ProQR Therapeutics N.V. (PRQR) AI Stock Analysis
PRQR AI stock analysis summary
AI ResearchProQR Therapeutics N.V. (PRQR) is a biotechnology company developing RNA-based therapeutics for genetic disorders. In FY2025, revenue fell 19.2% to $15.3M while net loss expanded to -$40.5M, though trailing twelve month revenue reached $18.4M with quarterly revenue growing 120.4% year-over-year. The company maintains a net cash position of $103.9M and holds an enterprise value of $123.4M.
- Market cap
- $184.9M
- Revenue (TTM)
- $18.4M
- P/E
- —
- 1Y return
- -53.2% S&P 500 16.8%
- Avg. target
- $7.78 493.7% vs last close
Bull case
- Analysts maintain 8 Strong Buy ratings and a mean price target of $7.78, implying 493.7% upside over the last closing price of $1.31.
- The company holds $117.1M in cash and short-term investments, providing a net cash buffer of $103.9M and a current ratio of 3.49.
- Revenue expanded at a 5-year CAGR of 71.5% between FY2020 and FY2025, with the latest quarter posting 120.4% year-over-year revenue growth.
Bear case
- The company remains unprofitable, reporting a net loss of -$40.5M in FY2025 and an operating cash outflow of -$52.8M.
- The stock has lost 53.2% over the trailing year and 83.4% over five years, trading near its 52-week low of $1.30.
- Shareholders have experienced substantial dilution, reflected in a 54.4% increase in the share count over the past five years.
What ProQR Therapeutics does
Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR Therapeutics N.V. is a biopharmaceutical company dedicated to advancing RNA-based therapeutics for genetic disorders. Its clinical pipeline features sepofarsen in phase II/III clinical trials for Leber congenital amaurosis 10, and ultevursen in phase II/III trials for USH2A-mediated retinitis pigmentosa and usher syndrome. The company utilizes its proprietary Axiomer RNA base-editing platform technology to design targeted genetic interventions. ProQR maintains strategic collaborations with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., Leiden University Medical Center, and a partnership with Eli Lilly and Company for genetic disorders of the liver and nervous system.
Growth and profitability
ProQR Therapeutics generated $1.3M in revenue in FY2021, which increased to $3.6M in FY2022 and $6.5M in FY2023. Revenue peaked at $18.9M in FY2024 before falling 19.2% to $15.3M in FY2025. Across the 5-year period from FY2020 to FY2025, revenue grew at a CAGR of 71.5%. Profitability remained negative, with net losses of -$60.7M in FY2021, -$64.4M in FY2022, -$28.1M in FY2023, -$27.8M in FY2024, and -$40.5M in FY2025. Gross margin was 100.0% through FY2024 before dropping to 83.0% in FY2025, alongside an operating margin of -275.9%. For the trailing twelve months ending June 30, 2026, revenue was $18.4M, aided by quarterly revenue growth of 120.4% year-over-year.
Balance sheet and cash flow
As of June 30, 2026, ProQR Therapeutics held $117.1M in cash and short-term investments against total debt of $13.2M, resulting in a net cash position of $103.9M. Total assets stood at $133.5M and shareholders' equity was $79.4M, supporting a current ratio of 3.49 and a debt-to-equity ratio of 0.17. In FY2025, operating cash flow was -$52.8M and free cash flow was -$53.8M, with capital expenditures of $1.0M. Over the past five years, the company's share count increased by 54.4%.
Valuation and performance
ProQR Therapeutics trades at a price-to-sales multiple of 10.0x and an enterprise value to revenue multiple of 5.9x, both above the median of its US-listed Healthcare peers, which carries a price-to-sales multiple of 4.1x. Its price-to-book ratio stands at 2.6x against an enterprise value of $123.4M and a market capitalization of $184.9M. The stock has underperformed the broader market, with a 1-year return of -53.2% compared to 16.8% for the S&P 500 (SPY). Over five years, the stock returned -83.4%, while SPY gained 83.0%.
What analysts expect
Wall Street coverage consists of 8 Strong Buy ratings and 1 Buy rating, with no Hold, Sell, or Strong Sell recommendations. The mean price target is $7.78, representing an upside of 493.7% from the last close of $1.31. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$0.45 and revenue of $20.5M. For the next fiscal year, 2 analysts project revenue of $18.4M and EPS of -$0.46. The company beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 5, 2026.
Key risks and what to watch
- Substantial negative free cash flow of -$53.8M in FY2025 highlights ongoing operational cash burn that could deplete liquidity.
- Annual revenue contracted 19.2% in FY2025 to $15.3M, and analysts expect revenue to decline another 10.3% in the next fiscal year.
- R&D expenditures of $40.7M in FY2025 continue to outpace total annual revenue of $15.3M, creating persistent earnings deficits.
- Trading 23.8% below its 200-day moving average and near its 52-week low of $1.30, the stock reflects sustained price pressure.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this PRQR AI stock analysis
This page is an AI-written research summary of ProQR Therapeutics N.V. (PRQR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: PRQR income statement, PRQR balance sheet, PRQR key metrics, PRQR analyst forecast, PRQR chart. See the PRQR stock overview for the latest quote and news.
PRQR AI stock analysis FAQ
What is ProQR Therapeutics' cash and debt position?
As of June 30, 2026, ProQR had $117.1M in cash and short-term investments and $13.2M in total debt. This leaves the company with $103.9M in net cash and a debt-to-equity ratio of 0.17.
Does ProQR Therapeutics pay a dividend?
No, ProQR Therapeutics does not pay a dividend. The company directs its capital toward research and development, which required $40.7M in expenditures in FY2025.
What are analysts forecasting for PRQR stock?
Analysts project FY2026 revenue of $20.5M and an EPS of -$0.45. The mean price target is $7.78 across 9 positive analyst ratings, indicating 493.7% upside from $1.31.
When is ProQR Therapeutics' next earnings announcement?
The company's next earnings date is scheduled for November 5, 2026. In the prior four quarters, ProQR beat analyst EPS estimates in 3 quarters.